Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.

Journal of hepatology - 1 Mar 2017

Toyoda Hidenori, Kumada Takashi, Tada Toshifumi, Shimada Noritomo, Takaguchi Koichi, Senoh Tomonori, Tsuji Kunihiko, Tachi Yoshihiko, Hiraoka Atsushi, Ishikawa Toru, Shima Toshihide, Okanoue Takeshi

Abstract excerpt

BACKGROUND & AIMS: Anti-hepatitis C virus (HCV) therapy by interferon (IFN)-free regimen with oral direct-acting antiviral drugs are tolerable in aged patients, with fewer adverse effects than IFN-based therapies. We investigated the efficacy and tolerability of an IFN-free anti-HCV therapy in extremely aged patients, as well as the survival benefit of sustained virologic response (SVR). METHODS: Following...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferons

Share to Isoquinolines

Share to Pyrrolidines

Share to Sulfonamides

Share to Sustained Virologic Response

Share to Valine

Source

Identifiers

PMID: 27890790
DOI: 10.1016/j.jhep.2016.11.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.PMID 27890790Read ↗

Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta-analysis.Semantic proximity Read ↗

Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.Semantic proximity Read ↗

Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.Semantic proximity Read ↗

The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.Semantic proximity Read ↗

Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study.Semantic proximity Read ↗

Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.Semantic proximity Read ↗

Virologic responses and tolerance of peginterferon alfa plus ribavirin treatment for patients with chronic hepatitis C virus infection in different age categories.Semantic proximity Read ↗

Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older.Semantic proximity Read ↗

Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2.Semantic proximity Read ↗

Various predictors of sustained virologic response in different age groups of patients with genotype-1 chronic hepatitis C.Semantic proximity Read ↗

Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.